Clinical Trials for Prostate Cancer
PHEN’s “Find Your Trial (FYT)” search tool connects patients with actively recruiting prostate cancer clinical trials that can possibly benefit them. The FYT tool has seven easy to use searchable categories to help patients find and review clinicals trials based on where they are on their prostate cancer journey. All trials listed have links to important information, including description, study locations, contacts and more.
All Trials
Find Your Trial
The FDA approves a new prostate cancer combination treatment based upon a successful clinical trial
The U.S. Food and Drug Administration (FDA) recently approved TALZENNA (talazoparib) in combination with XTANDI (enzalutamide) for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer...
Omaha-004 Patient Summary – Metastatic Castration Resistant
This clinical trial is for participants who have metastatic castration-resistant prostate cancer (mCRPC) and whose cancer progressed on or after they were previously treated with next-generation Hormonal Agent (NHA). Study of Investigational Drug, MK5684, in...
PHEN’s Educational Resources Highlighted During Recent May Meeting
Newly diagnosed prostate cancer patients often don’t know where to start. That’s why PHEN’s Prostate Cancer Disparity Rally held in April emphasized patient educational resources to help men learn about early detection as well as better understand their treatment...
C2321001 Patient Summary – Metastatic Castration Resistant
This trial is no longer actively recruiting.Prostate cancer is one of the most common types of cancer. Unfortunately, prostate cancer can often become resistant to hormone therapy and continue to progress despite ongoing treatment. When this occurs, it is called...
AMG 340 Patient Summary – Metastatic Castration Resistant
This study evaluates safety and the performance of AMG 340 in men with metastatic castrate-resistant prostate cancer (mCRPC). TNB-585 is a novel bispecific antibody, which binds to PSMA on prostate cancer cells and the CD3 molecule on T-cells (immune cell). It is...
AMG 509 Patient Summary – Metastatic Castration Resistant
This trial is no longer recruiting.This clinical trial is for patients who have metastatic castration resistant prostate cancer (mCRPC) and failed to respond to abiraterone acetate or enzalutamide (but not both) and to taxane-based chemotherapy. Study of AMG 509 in...
MK-5684-01A Patient Summary – Metastatic Castration Resistant
Background Information Metastatic castration-resistant prostate cancer (mCRPC) is a form of prostate cancer that keeps growing even when male hormones like testosterone are decreased to very low levels. Current treatments include drugs that block these hormones,...
AMG 757 Patient Summary – Metastatic Castration Resistant
This trial is no longer actively recruiting.This study evaluates the safety and the maximum dose that can be handled by patients in this trial. A Study of AMG 757 bispecific antibody therapy in men with Neuroendocrine Prostate Cancer (NEPC) Patient Summary AMG 757...
CheckMate 7DX Patient Summary – Metastatic Castration Resistant
This trial is no longer actively recruiting.The purpose of this study is to test the safety and efficacy of nivolumab with docetaxel in men with advanced castration resistant prostate cancer (mCRPC), who have progressed after second-generation hormonal manipulation. A...
Tamarack Patient Summary – Metastatic Castration Resistant
Scientists have developed a new generation of targeted drugs called antibody-drug conjugates (ADCs) with the potential to treat metastatic castrate-resistant prostate cancer. ADCs use the targeting power of antibodies to precisely deliver small amounts of chemotherapy...
Find Your Trial
Low Risk
Intermediate Risk
High Risk
Cancer Recurrence
Non-Metastatic Castration Resistant
Metastatic Castration Sensitive
Metastatic Castration Resistant
This information is for educational purposes only and not intended as medical advice.
Patients should consult their medical doctor for advice and recommendations about specific clinical trials.